Skip to main
  1. Stocks
  2. Evolus
  3. Forecast
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is supported by resilient demand in the cash-pay aesthetics market, with Q3 revenue of $78.0M, up 13% year over year and slightly ahead of consensus, while adjusted EBITDA turned positive for a fourth consecutive quarter at $1.2M. The company is also broadening its growth base beyond Jeuveau through Evolysse, which generated $7.9M and reached more than 4,500 customers, alongside strong retention metrics including a cumulative reorder rate above 70% and rewards membership above 1.6M. Management’s maintained FY26 revenue guidance of $330M-$337M, tightened opex outlook, and reaffirmed 2028 targets, combined with a visible pipeline of launches, support the view that Evolus can scale revenue and margin expansion over time.

Bears say

Evolus is facing a more cautious outlook because outyear revenue estimates were modestly reduced to reflect more conservative toxin market growth assumptions, signaling slower category expansion than previously expected. Although the revision has only a minimal impact on adjusted EBITDA estimates, it still points to limited near-term operating leverage and suggests that incremental sales growth may not translate meaningfully into stronger profitability. With Jeuveau and Evolysse dependent on sustained demand in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia, a softer growth backdrop raises concerns about the company’s ability to accelerate fundamentals.

Evolus (EOLS) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Evolus (EOLS) Analyst Forecast & Price Prediction

Get the latest Evolus (EOLS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Evolus (EOLS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Evolus (EOLS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Evolus (EOLS) Analyst Forecast & Price Prediction

Get the latest Evolus (EOLS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Evolus (EOLS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EOLS stock data and trends